FDA has approved an antipsychotic medication, haloperidol injection, USP (Sagent Pharmaceuticals), indicated for use in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette's disorder.
FDA has approved an antipsychotic medication, haloperidol injection, USP (Sagent Pharmaceuticals), indicated for use in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette's disorder.
Haloperidol will be offered in 5 mg/mL single-dose and 50 mg/10 mL multi-dose, latex-free vials.
According to 2011 IMS data, the annual U.S. injectable market for haloperidol approximated $12.5 million.
As with all products in Sagent's portfolio, haloperidol features the company's PreventIV Measures packaging and labeling, designed to aid in the reduction of medication errors.
Sagent expects to launch the product early in the fourth quarter.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.